Ernexa Therapeutics Inc. short interest in 2024
In 2024, Ernexa Therapeutics Inc.'s disclosed short interest ran from 2.45% of shares outstanding on 12 Jan 2024 to 4.45% on 31 Dec 2024, a change of +2.00 percentage points. The year's high was 4.45% on 31 Dec 2024 and its low 0.61% on 30 Aug 2024, averaging 1.30% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.77 days on 15 Feb 2024. Full history: Ernexa Therapeutics Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 2.45% (12 Jan 2024)
- End of year
- 4.45% (31 Dec 2024)
- Change
- +2.00 pp
- High
- 4.45% (31 Dec 2024)
- Low
- 0.61% (30 Aug 2024)
- Average
- 1.30%
- Highest days to cover
- 17.77 (15 Feb 2024)
- SEC filings marked
- 4
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 2.45% | 12.48 | |
| 31 Jan 2024 | 2.73% | 15.42 | |
| 15 Feb 2024 | 2.71% | 17.77 | |
| 15 Mar 2024 | 0.62% | 1.72 | 10-K filed |
| 28 Mar 2024 | 0.78% | 6.22 | |
| 15 Apr 2024 | 0.74% | 10.42 | |
| 30 Apr 2024 | 0.63% | 5.00 | |
| 15 May 2024 | 0.98% | 4.36 | 10-Q filed |
| 31 May 2024 | 0.88% | 5.73 | |
| 14 Jun 2024 | 1.02% | 14.08 | |
| 28 Jun 2024 | 1.01% | 9.42 | |
| 15 Jul 2024 | 0.95% | 9.54 | |
| 31 Jul 2024 | 0.70% | 2.24 | |
| 15 Aug 2024 | 0.68% | 6.10 | 10-Q filed |
| 30 Aug 2024 | 0.61% | 12.53 | |
| 13 Sep 2024 | 0.68% | 3.94 | |
| 30 Sep 2024 | 1.01% | 1.00 | |
| 15 Oct 2024 | 1.13% | 2.62 | |
| 31 Oct 2024 | 0.82% | 1.02 | |
| 15 Nov 2024 | 0.88% | 1.00 | 10-Q filed |
| 29 Nov 2024 | 2.13% | 1.00 | |
| 31 Dec 2024 | 4.45% | 1.00 |
See also: Ernexa Therapeutics Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.